Loading clinical trials...
Loading clinical trials...
A Phase Ib/II Trial To Test The Safety And Efficacy Of Vaccination With HPV16-E711-19 Nanomer For The Treatment Of Incurable HPV 16-Related Oropharyngeal, Cervical And Anal Cancer In HLA-A*02 Positive Patients
Conditions
Interventions
DPX-E7 vaccine
Cyclophosphamide
Locations
1
United States
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Start Date
March 30, 2017
Primary Completion Date
October 4, 2019
Completion Date
February 6, 2023
Last Updated
January 11, 2024
NCT07125755
NCT04767048
NCT05179824
NCT05070247
NCT02296684
NCT07259915
Lead Sponsor
Dana-Farber Cancer Institute
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions